AMGN logo

Amgen Inc.

AMGN
Healthcare|Drug Manufacturers - General|US
$460.42
+0.14 (+0.03%)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38

Clinical Trials (542)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT06180278
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum Disorder
P4
Active32Open-labelInebilizumab
NCT04951856
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
P4
Active2,166RCT, Open-labelEvolocumab 140 MG/ML, Standard of care (SOC)
NCT07866066
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
P3
Recruiting1,300RCT, Open-labelMaridebart cafraglutide, Semaglutide
NCT07684235
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Obesity, Overweight
P3
Recruiting3,200RCT, Double-blindMaridebart cafraglutide, Placebo
NCT07005128
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
P3
Active350RCT, Open-labelTarlatamab, Durvalumab, Carboplatin, Etoposide
NCT03969329
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Secondary Hyperparathyroidism
P3
Recruiting24Open-labelEtelcalcetide
NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
P3
Recruiting750RCT, Open-labelSotorasib, Pembrolizumab
NCT06321601
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
Vasculitis
P3
Active19Open-labelAvacopan
NCT04528082
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
Behçet Disease
P3
Recruiting60RCT, Double-blindApremilast, Placebo
NCT06248619
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
Thyroid Eye Disease
P3
Active89RCT, Double-blindTeprotumumab
NCT06858878
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
P3
Active1,105RCT, Double-blindMaridebart cafraglutide, Placebo
NCT07293260
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Cardiovascular Disease
P3
Recruiting406RCT, Double-blindOlpasiran, Placebo
NCT07225686
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Obesity, Obstructive Sleep Apnea
P3
Active250RCT, Double-blindMaridebart cafraglutide, Placebo
NCT07778316
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Small Cell Lung Cancer
P3
Recruiting400RCT, Open-labelTarlatamab
NCT06883305
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Chronic Obstructive Pulmonary Disease (COPD)
P3
Recruiting990RCT, Double-blindTezepelumab
NCT06691984
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
P3
Active707RCT, Open-labelXaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
NCT06054555
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Melanoma
P3
Active633RCT, Double-blindABP 206, Nivolumab
NCT07851220
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Glomerulonephritis, Membranous
P3
Recruiting159RCT, Open-labelInebilizumab, Tacrolimus
NCT03633708
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Secondary Hyperparathyroidism, Chronic Kidney Disease
P3
Recruiting56RCT, Open-labelEtelcalcetide
NCT03289299
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
Smoldering Multiple Myeloma
P2
Active87Open-labelCarfilzomib, Lenalidomide, Daratumumab, Dexamethasone
NCT05074810
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Non Small Cell Lung Cancer, KRAS Activating Mutation
P1P2
Active153Open-labelavutometinib and sotorasib, avutometinib and sotorasib and defactinib
NCT05848687
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Lymphoblastic Leukemia
P1P2
Recruiting90Open-labelDexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib
NCT02925234
The Drug Rediscovery Protocol (DRUP Trial)
Cancer, Tumors
P2
Recruiting1,550Open-labelPanitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib
NCT06529731
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia, Myelodysplastic Syndromes
P2
Recruiting57Open-labelInterferon gamma-1b, Donor Leukocyte Infusion (DLI)
NCT03114865
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
P1P2
Active44Open-labelBlinatumomab 9ug, Blinatumomab 28 ug, Blinatumomab, Dexamethasone
NCT06680622
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
Metastatic Gastro-esophageal Adenocarcinoma
P2
Active126Open-labelbemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
NCT07172919
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Advanced Solid Tumors
P2
Recruiting14Open-labelSotorasib, Panitumumab
NCT05060016
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Relapsed/Refractory Small Cell Lung Cancer
P2
Active222RCT, Open-labelTarlatamab
NCT02415413
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
P2
Active90Open-labelcarfilzomib, Lenalidomide, Dexamethasone, Melphalan
NCT04176718
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Multiple Myeloma, Refractory Multiple Myeloma
P2
Active44Open-labelDaratumumab, Carfilzomib, Pomalidomide, Dexamethasone
NCT06660810
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
Soft Tissue Sarcoma, Sarcoma,Soft Tissue
P2
Active2Open-labelTalimogene Laherparepvec
NCT04599062
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
Soft Tissue Sarcoma
P1P2
Active8Open-labelTalimogene Laherparepvec
NCT05789303
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Multiple Myeloma, Relapse Multiple Myeloma
P2
Recruiting83Open-labelBelantamab mafodotin, Carfilzomib, Pomalidomide, Dexamethasone
NCT07441252
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Overweight or Obesity and Elevated Liver Fat
P2
Active180RCT, Double-blindMaridebart cafraglutide, Placebo
NCT06570798
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
P2
Recruiting220Open-labelInebilizumab, Blinatumomab
NCT06401044
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Thyroid Eye Disease
P1P2
Active94RCT, Double-blindAMG 732
NCT03500445
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Myeloma, Multiple Myeloma
P2
Active75Open-labelDaratumumab, Carfilzomib, Lenalidomide, Dexamethasone
NCT06593522
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
MTAP-deleted NSCLC
P2
Active61RCT, Open-labelanvumetostat
NCT04822337
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Multiple Myeloma
P1P2
Recruiting70Open-labelCarfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
NCT07037758
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Extensive Stage Small Cell Lung Cancer
P1
Recruiting380Open-labelTarlatamab, AB248
NCT07531095
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer
P1
Recruiting160Open-labelZL-1310, Tarlatamab, Durvalumab
NCT07493512
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
P1
Recruiting40Open-labelXaluritamig
NCT07160257
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
P1
Active56RCT, Double-blindMaridebart cafraglutide, Placebo
NCT05361395
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Extensive Stage Small Cell Lung Cancer
P1
Active184Open-labelTarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab
NCT07297979
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Ewing Sarcoma
P1
Recruiting50Open-labelXaluritamig
NCT04221542
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
P1
Recruiting479RCT, Open-labelAMG 509, Abiraterone, Enzalutamide
NCT07094113
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
KRAS Altered Advanced or Metastatic Solid Tumors
P1
Recruiting434Open-labelAMG 410, Pembrolizumab, Panitumumab
NCT07102394
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
NF1, Neurofibromatosis
P1
Recruiting10Open-labelImlygic
NCT06898957
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer
P1
Active29Open-labelYL201, Tarlatamab, Durvalumab
NCT07811999
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
Healthy Participants
P1
Recruiting308RCT, Open-labelRomosozumab
NCT07745907
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
Healthy Participants
P1
Recruiting28RCT, Open-labelAMG 691
NCT07013578
TIDHI Mental Health in IBD Patients Study
Crohn Disease (CD), Ulcerative Colitis (UC)
N/A
Recruiting100RCT, Open-label—
NCT04151342
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Cancer, Malignancies Multiple
Recruiting5,500—Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.
NCT01277419
German Spondyloarthritis Inception Cohort
Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
Recruiting1,000——
NCT02009345
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Familial Hypercholesterolemia, Lipid Disorder
Recruiting6,000——
NCT01848028
PsoBest - The German Psoriasis Registry
Psoriasis, Psoriatic-arthritis
Recruiting3,500——
NCT02622581
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic
Recruiting14,500——
NCT05001087
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
Multiple Myeloma
Recruiting1,900——
NCT07478887
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
Cardiovascular Risk, LDL-C
N/A
Recruiting1,000Open-label—
NCT05885607
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Active40——
NCT06295679
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
Active7,000——
NCT06471036
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
ASCVD, LDL-C
N/A
Recruiting400RCT, Open-label—
NCT05909761
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Recruiting60—UPLIZNA
NCT03168529
Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit
Heart Failure
P4
Terminated19RCT, Double-blindIvabradine, Placebo
NCT00640393
Safety and Efficacy of Combining nbUVB to Etanercept in Patients
Psoriasis Vulgaris
P4
Completed99RCT, Single-blindEtanercept
NCT03851263
Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion
Coronary Artery Disease
P4
Withdrawn—Open-labelEvolocumab
NCT00967538
Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments
Psoriasis
P4
Completed89Open-labeletanercept 50 mg
NCT04252742
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
Migraine
P4
Completed512RCT, Double-blindErenumab, Placebo
NCT02749370
Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast
Plaque Psoriasis
P4
Completed80Open-labelEtanercept
NCT03331666
Impact of LDL-cholesterol Lowering on Platelet Activation
Familial Hypercholesterolemia
P4
Terminated4RCT, Double-blindEvolocumab
NCT00791765
Moderate to Severe Plaque Psoriasis With Scalp Involvement
Psoriasis
P4
Completed124RCT, Double-blindEtanercept, Placebo
NCT02346877
Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis
Persistence to Enbrel
P4
Terminated19Open-label—
NCT00094341
Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes
Rheumatoid Arthritis
P4
Completed215RCT, Open-labelEtanercept
NCT03087851
Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
Osteoporosis
P4
Completed61RCT, Open-labelZoledronic Acid
NCT00332332
Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis
Psoriasis
P4
Completed246Open-labeletanercept
NCT01563185
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
P4
Completed12Open-label800 mg ibuprofen/26.6 mg famotidine
NCT04772313
Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy
Uncontrolled Gout
P4
Completed11Open-labelPegloticase, Methotrexate (MTX)
NCT00111124
Enbrel® in Psoriatic Arthritis
Psoriasis
P4
Completed——Enbrel®
NCT01543204
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Psoriasis
P4
Terminated64Open-labelEtanercept
NCT03456856
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Heart Failure (HF)
P4
Completed30Open-labelIvabradine
NCT04506086
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
B-precursor Acute Lymphoblastic Leukemia
P4
Terminated10Open-labelBlinatumomab
NCT02101164
Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
Solid Tumor, Metastatic Bone Disease
P4
Withdrawn—RCT, Open-labeldenosumab, pamidronate
NCT03994731
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Gout
P4
Completed152RCT, Double-blindPegloticase, methotrexate, placebo, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone
NCT03301857
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Giant Cell Tumor of Bone
P4
Completed85Open-labelDenosumab
NCT04306081
Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
P4
Unknown86RCT, Double-blindEvolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.
NCT03912337
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
Migraine
P4
Terminated29RCT, Double-blindPlacebo, Erenumab
NCT00127842
REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
Psoriatic Arthritis
P4
Completed110Open-labelEtanercept
NCT00277160
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Neutropenia, Breast Cancer
P4
Completed852RCT, Open-labelNeulasta (pegfilgrastim)
NCT03335488
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
Urea Cycle Disorder
P4
Completed16RCT, Open-labelRAVICTI, NaPBA
NCT00259610
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
Rheumatoid Arthritis
P4
Completed755RCT, Double-blindmethotrexate, sulfasalazine, hydroxychloroquine, etanercept
NCT00833729
The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab
Plaque Psoriasis
P4
Completed10Open-labeletanercept
NCT00803712
20070360 Incident Dialysis
Chronic Kidney Disease, Secondary Hyperparathyroidism
P4
Completed313RCT, Open-labelCinacalcet, Vitamin D
NCT00121433
Leptin and Endothelial Function
Healthy
P4
Completed15RCT, Double-blindleptin
NCT07803679
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Coronary Artery Disease, Hypercholesterolemia
P4
Not Yet Recruiting308RCT, Single-blindEvolocumab, Routine Lipid Management
NCT01009879
Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants
Rheumatoid Arthritis
P4
Withdrawn—Open-labelEtanercept
NCT00111995
Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
Chronic Renal Failure, Anemia
P4
Completed400RCT, Double-blindAranesp®
NCT00153868
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
Anemia, Cancer
P4
Completed43Open-labeldarbepoetin alfa
NCT00132418
Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders
Rheumatoid Arthritis
P4
Completed564RCT, Double-blindEnbrel, Placebo
NCT04249427
Erenumab for Idiosyncratic Facial Pain
Facial Pain, Rhinosinusitis
P4
Completed29RCT, Double-blindErenumab Prefilled Syringe
NCT00353119
A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
P3
Completed15RCT, Double-blindPlacebo comparator, Etanercept
NCT03029234
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
P3
Completed126Open-labelDexamethasone, Carfilzomib
NCT01966003
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer Metastatic
P3
Completed642RCT, Double-blindCarboplatin, Paclitaxel, ABP 215, Bevacizumab
NCT02126449
DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer
Fasting Mimicking Diet, Breast Cancer
P2P3
Completed131RCT, Open-label—
NCT01901146
Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer
Breast Cancer
P3
Completed725RCT, Double-blindABP 980, Trastuzumab, Paclitaxel
NCT01652872
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Anemia in Chronic Kidney Disease Patients Not on Dialysis
P3
Completed756RCT, Double-blindDarbepoetin alfa
NCT05062759
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
Moderate to Severe Asthma
P3
Completed70RCT, Double-blindTezepelumab, Placebo
NCT01568866
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Multiple Myeloma
P3
Completed929RCT, Open-labelCarfilzomib, Bortezomib, Dexamethasone
NCT01697072
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Gastric Cancer
P3
Terminated609RCT, Double-blindRilotumumab, Epirubicin, Cisplatin, Capecitabine
NCT06224192
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
P3
Completed151RCT, Open-label—
NCT05882877
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Atopic Dermatitis
P3
Terminated2,621RCT, Double-blindRocatinlimab
NCT01925768
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
Psoriatic Arthritis
P3
Completed219RCT, Double-blindApremilast 30 mg, Placebo
NCT01849497
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Primary Hypercholesterolemia, Mixed Dyslipidemia
P3
Completed149RCT, Open-labelEvolocumab Pre-filled Syringe, Evolocumab AI/pen
NCT03300609
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
Colorectal Adenocarcinoma, RAS Wild Type
P3
Terminated4RCT, Open-labelPanitumumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Capecitabine
NCT02016716
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
P3
Completed294RCT, Double-blindRomosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL
NCT01180634
MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis
Cystic Fibrosis
P3
Completed330RCT, Double-blindAeroquin, Placebo
NCT01161498
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
Squamous Cell Carcinoma, Head and Neck Cancer
P3
Terminated5RCT, Open-labelTalimogene Laherparepvec, Cisplatin
NCT00116701
Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis
Kidney Disease
P3
Completed200Open-labelAranesp®
NCT01302392
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
P3
Completed315RCT, Open-labelCarfilzomib, Best Supportive Care
NCT02792699
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab
Arthritis, Rheumatoid
P3
Completed311RCT, Double-blindABP 798, Rituximab (US), Rituximab (EU)
NCT00925600
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Cancer, Cataract
P3
Completed769RCT, Double-blindDenosumab, Placebo
NCT03832998
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Migraine
P3
Completed284RCT, Double-blindErenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
NCT01196715
Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes
Myelodysplastic Syndrome
P3
Completed360RCT, Open-labelDarbepoetin alpha, Filgrastim
NCT00980174
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
Low Bone Mass, Low Bone Mineral Density
P3
Completed242RCT, Double-blind60 mg denosumab
NCT00111111
An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis
Psoriasis
P3
Completed—RCT, Open-labelEtanercept
NCT00950911
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
P3
Completed35Open-labelamg 162
NCT00144755
R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma
Diffuse Large Cell Lymphoma
P3
Completed600RCT, Open-labelDarbepoetin alfa
NCT00089791
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
Osteoporosis
P3
Completed7,808RCT, Double-blindplacebo, Denosumab
NCT00936897
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
Postmenopausal Osteoporosis
P3
Completed833RCT, Open-labelIbandronate, Denosumab
NCT03706079
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Asthma
P3
Completed951RCT, Double-blindTezepelumab
NCT00557817
Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
Hematological Malignancies
P2P3
Completed125RCT, Open-labelDarbepoetin alpha (Aranesp), Iron saccharate (Venofer)
NCT03930186
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
Plaque Psoriasis
P3
Completed152Open-labelApremilast, Topical Therapy
NCT01763827
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Hyperlipidemia
P3
Completed615RCT, Double-blindEvolocumab, Ezetimibe, Placebo to Evolocumab
NCT07637513
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Limited Stage Small-Cell Lung Cancer
P3
Not Yet Recruiting430RCT, Open-labelTarlatamab, Durvalumab
NCT06122649
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
Plaque Psoriasis
P3
Completed203RCT, Double-blindapremilast, Placebo
NCT00785421
Chemotherapy With or Without Enoxaparin in Pancreatic Cancer
Pancreatic Cancer
P2P3
Completed312RCT, Open-labelenoxaparin, chemotherapy with LMWH - enoxaparin, only chemotherapy
NCT00111137
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Cancer, Non-Myeloid Malignancies
P3
Completed718RCT, Open-labelrHuEPO, Darbepoetin alfa
NCT01493505
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Fallopian Tube Cancer, Ovarian Cancer
P3
Terminated1,015RCT, Double-blindAMG 386, Paclitaxel, AMG 386 Placebo, Carboplatin
NCT02352753
Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
Osteogenesis Imperfecta
P3
Terminated153Open-labelDenosumab
NCT03811418
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
Advanced Breast Cancer, HER2-positive Breast Cancer
P3
Withdrawn—RCT, Open-labelTrastuzumab, Pertuzumab, Vinorelbine, Docetaxel
NCT00523341
Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
Osteopenia, Osteoporosis
P3
Completed4,550Open-labelDenosumab
NCT02797080
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Friedreich's Ataxia
P3
Completed38Open-labelinterferon γ-1b
NCT01281254
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
Fallopian Tube Cancer, Ovarian Cancer
P3
Terminated223RCT, Double-blindAMG386 plus PLD, Placebo plus PLD
NCT02189837
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Primary Hyperlipidemia and Mixed Dyslipidemia
P3
Completed89RCT, Double-blindEvolocumab, Atorvastatin, Placebo to Evolocumab, Placebo to Atorvastatin
NCT02175277
Darbepoetin Alfa MDS Companion Protocol
Myelodysplastic Syndrome (MDS)
P3
Completed9Open-labelDarbepoetin Alfa
NCT01099436
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients
Breast Cancer
P3
Completed250RCT, Open-labelcyclophosphamide, docetaxel, doxorubicin hydrochloride, zoledronic acid
NCT00117624
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
Anemia
P3
Completed—RCT, Double-blinddarbepoetin alfa
NCT02593773
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Friedreich's Ataxia
P3
Completed86Open-labelInterferon γ-1b
NCT00035594
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
Neutropenia
P3
Completed928RCT, Double-blindpegfilgrastim
NCT05198934
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Colorectal Cancer (CRC)
P3
Completed160RCT, Open-labelSotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib
NCT00984815
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
Osteoarthritis, Rheumatoid Arthritis
P3
Completed86Open-labelHZT-501
NCT00364013
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Metastatic Colorectal Cancer
P3
Completed1,183RCT, Open-labelPanitumumab, FOLFOX regimen
NCT05704725
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
Chorioretinal Vascular Disease
P3
Completed49RCT, Open-labelABP 938, Aflibercept
NCT03131453
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Alzheimers Disease
P2P3
Terminated1,145RCT, Double-blindCNP520 50mg, CNP520 15mg
NCT00838201
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Cancer, Carcinoma
P3
Completed384Open-labelDenosumab
NCT02263508
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Melanoma
P3
Terminated713RCT, Double-blindTalimogene Laherparepvec, Pembrolizumab, Placebo
NCT03432533
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
Post-Menopausal Osteoporosis
P3
Completed283RCT, Open-labelromosozumab HCP administration with PFS
NCT01953328
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
P3
Completed409RCT, Double-blindAtorvastatin, Evolocumab
NCT04761627
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Psoriasis
P3
Completed494RCT, Double-blindUstekinumab, ABP 654
NCT01879319
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Primary Hypercholesterolemia, Mixed Dyslipidemia
P3
Completed164RCT, Open-labelEvolocumab AMD, Evolocumab AI/pen
NCT04851964
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
Chronic Rhinosinusitis With Nasal Polyps
P3
Completed416RCT, Double-blindExperimental: Tezepelumab, Mometasone furoate or equivalent intranasal corticosteroid
NCT01270347
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Cystic Fibrosis
P3
Completed282RCT, Open-labelMP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution)
NCT00357903
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Rheumatoid Arthritis
P3
Completed639Open-labelEtanercept
NCT00110955
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Anemia, Non-Myeloid Malignancies
P3
Completed391RCT, Double-blindDarbepoetin alfa, Placebo
NCT03287609
EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Acute Coronary Syndrome
P3
Completed308RCT, Double-blindEvolocumab 140 mg/mL, Placebo
NCT05704738
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Atopic Dermatitis
P3
Completed532RCT, Double-blindRocatinlimab, Placebo
NCT00121602
Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease
Anemia, Kidney Disease
P3
Completed446RCT, Double-blindDarbepoetin Alfa
NCT00345839
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
Secondary Hyperparathyroidism, Chronic Kidney Disease
P3
Completed3,883RCT, Double-blindCinacalcet, Placebo
NCT00146224
Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis
Nephrology
P3
Completed420RCT, Double-blindEpoetin alfa RB, Epoetin alfa DT
NCT01307423
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Psoriatic Arthritis
P3
Completed529RCT, Double-blindApremilast 20mg, Apremilast 30mg, Placebo
NCT01854918
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
Hyperlipidemia and Mixed Dyslipidemia
P3
Completed3,681RCT, Open-labelEvolocumab, Standard of Care
NCT00110903
Treatment for Subjects With Active Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
P3
Completed—Open-labelEtanercept Liquid
NCT01194219
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
P3
Completed844RCT, Double-blindApremilast, Placebo, Topical treatments or phototherapy
NCT00116688
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
P3
Completed313RCT, Open-labelRomiplostim
NCT05633355
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Atopic Dermatitis
P3
Completed187Open-labelRocatinlimab
NCT03968978
Tezepelumab Home Use Study
Asthma
P3
Completed216RCT, Open-labelTezepelumab (APFS), Tezepelumab (AI)
NCT00339183
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
Metastatic Colorectal Cancer
P3
Completed1,186RCT, Open-labelPanitumumab, FOLFIRI
NCT00135317
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
Cancer
P3
Completed—RCT, Open-labeldarbepoetin alfa
NCT05899816
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
P3
Completed221RCT, Double-blindRocatinlimab, Placebo
NCT00769704
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
Melanoma
P3
Completed437RCT, Open-labelTalimogene laherparepvec, GM-CSF
NCT01212770
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
P3
Completed505RCT, Double-blindApremilast 20mg, Apremilast 30mg, Placebo
NCT00111436
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
Psoriasis
P3
Completed912Open-labelEtanercept
NCT02125344
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III
P3
Completed961RCT, Open-labelnon-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Pertuzumab, Trastuzumab, Ferric carboxymaltose
NCT03701763
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Psoriasis
P3
Completed245RCT, Double-blindApremilast (CC-10004)
NCT00109031
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Cancer, Lymphoma
P3
Completed47RCT, Double-blindpalifermin, Cyclophosphamide, Etoposide, Placebo
NCT00508820
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
P3
Completed407Open-labelRomiplostim
NCT01235442
Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Psoriasis
P3
Completed592RCT, Single-blind1=Etanercept, 2=Clobetasol propionate foam
NCT00947297
Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
Urea Cycle Disorders
P3
Completed60Open-labelHPN-100
NCT02867813
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Dyslipidemia
P3
Completed5,035Open-labelEvolocumab
NCT00119613
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
Small Cell Lung Cancer
P3
Completed600RCT, Double-blindplacebo, darbepoetin alfa
NCT04607980
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
P3
Completed563RCT, Double-blindABP 654, Ustekinumab
NCT02729025
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
Subjects With Hyperlipidemia, Dyslipidemia
P3
Completed129RCT, Double-blindEvolocumab, Placebo
NCT04590586
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
COVID-19
P3
Completed515RCT, Double-blindStandard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo
NCT00518531
Denosumab Adherence Preference Satisfaction Study
Osteoporosis
P3
Completed250RCT, Open-labelalendronate, denosumab
NCT00992459
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
Urea Cycle Disorders
P3
Completed46RCT, Double-blindHPN-100, Buphenyl (NaPBA)
NCT04338581
Evaluation of AMG 714 for Vitiligo
Vitiligo
P2
Completed60RCT, Double-blindAMG 714, Placebo
NCT07178912
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Phase II Clinical Trial, Blinatumomab
P2
Not Yet Recruiting60Open-labelBlinatumomab, olverembatinib
NCT00193479
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
P2
Completed51Open-labelCyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab
NCT00940316
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Colorectal Cancer
P2
Completed28RCT, Open-labelpanitumumab, erlotinib hydrochloride, irinotecan hydrochloride
NCT00400764
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
Non-Hodgkin's Lymphoma
P1P2
Terminated72RCT, Open-labelDulanermin, Rituximab
NCT00632541
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Metastatic Breast Cancer
P2
Terminated18Open-labelSorafenib, Bevacizumab
NCT05054725
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Non-Small Cell Lung Cancer
P2
Completed47Open-labelRMC-4630, Sotorasib
NCT04448834
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
B-cell Acute Lymphoblastic Leukemia
P2
Withdrawn—Open-labelBlinatumomab
NCT03301467
Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
C3 Glomerulopathy (C3G)
P2
Completed57RCT, Double-blindAvacopan, Avacopan Matching Placebo
NCT04169347
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Colorectal Cancer Metastatic
P2
Unknown27Open-labelOxaliplatin
NCT00346099
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
Rectal Cancer, Neoplasm Metastasis
P2
Withdrawn—Open-labelPanitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation
NCT00591851
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
Breast Cancer
P2
Completed70Open-labelAC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
NCT01464034
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
P1P2
Terminated136Open-labelCarfilzomib, Pomalidomide, Dexamethasone
NCT06068153
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
Metastatic Non Small Cell Lung Cancer, KRAS G12C
P2
Withdrawn—Open-labelSotorasib, Lenvatinib
NCT00293202
Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients
End Stage Renal Disease
P2
Terminated10RCT, Double-blindEtanercept, Placebo
NCT00508625
A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
Non-Small Cell Lung Cancer
P2
Completed213RCT, Open-labelAMG 951 (rhApo2L/TRAIL), Bevacizumab, Carboplatin, Paclitaxel
NCT05180422
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Non Small Cell Lung Cancer
P1P2
Withdrawn—Open-labelAMG 510, MVASI
NCT00585650
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
Psoriasis
P1P2
Completed20RCT, Double-blindEtanercept
NCT03815279
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
Multiple Myeloma, Smoldering Multiple Myeloma
P2
By Invite80Open-labelCarfilzomib, Lenalidomide, Dexamethasone
NCT03931642
BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation
Richter Syndrome
P2
Completed41Open-labelRCHOP, Blinatumomab
NCT00050674
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Non-small Cell Lung Cancer
P2
Completed40Open-labelFilgrastim-SD/01
NCT04631601
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
P1P2
Terminated55RCT, Open-labelAcapatamab, Enzalutamide, Abiraterone, AMG 404
NCT02174861
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
Treatment for Prevention of Chronic Migraine
P2
Completed609Open-labelErenumab
NCT00613730
Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
Cancer of Pancreas, Cancer of the Pancreas
P2
Terminated3Open-labelGemcitabine, panitumumab
NCT02128230
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
Multiple Myeloma
P2
Terminated20Open-labelInduction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
NCT02630459
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Migraine
P2
Completed475RCT, Double-blindPlacebo, Erenumab, Erenumab
NCT01832727
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
P1P2
Terminated65Open-labelOprozomib, Dexamethasone
NCT01126112
Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer
Colorectal Cancer
P2
Completed33Open-labelPanitumumab
NCT01690143
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
Multiple Myeloma
P1P2
Completed45Open-labelCarfilzomib, Melphalan
NCT00104650
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
P2
Completed111RCT, Open-labelIV Bisphosphonate q 4 weeks
NCT01916109
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Bladder Cancer
P2
Terminated4Open-labelGemcitabine, Carboplatin, Panitumumab
NCT00947544
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
Urea Cycle Disorders
P2
Completed17Open-labelHPN-100, NaPBA
NCT00095264
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
Myelodysplastic Syndromes
P2
Completed209Open-labelDarbepoetin Alfa
NCT03982992
Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation, B-Cell Acute Lymphoblastic Leukemia
P2
Withdrawn—Open-labelBlinatumomab in combination with donor lymphocyte infusion
NCT03160079
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
B-Cell Acute Lymphoblastic Leukemia, Adult
P1P2
Completed16Open-labelblinatumomab, pembrolizumab
NCT02052882
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Isolated Chemotherapy-induced Thrombocytopenia
P2
Completed60Open-labelromiplostim
NCT00756444
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of Head and Neck
P2
Completed67RCT, Open-labelPanitumumab, Cisplatin, 5FU
NCT01712009
NOLAN: Naproxen or Loratadine and Neulasta
Bone Pain in Stage I - III Breast Cancer
P2
Completed600RCT, Open-labelNaproxen, Loratadine, Pegfilgrastim, Chemotherapy
NCT03809663
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
Atopic Dermatitis
P2
Terminated251RCT, Double-blindTezepelumab
NCT00194753
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12
Breast Neoplasm
P2
Completed80Open-labelPaclitaxel, Doxorubicin, Cyclophosphamide, G-CSF
NCT00072319
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Breast Cancer
P2
Completed——filgrastim, cyclophosphamide, epirubicin hydrochloride, paclitaxel
NCT00540657
A Phase II Study of CCX282-B in Patients With Celiac Disease
Celiac Disease
P2
Completed90RCT, Double-blindCCX282-B, Placebo
NCT02334306
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
P2
Completed32RCT, Double-blindAMG 557/MEDI5872
NCT02682693
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Breast Cancer Female NOS, Tubular Breast Cancer Stage II
P2
Completed780RCT, Open-labelDenosumab, nab-Paclitaxel, Epirubicin, Cyclophosphamide, Carboplatin, Trastuzumab, Pertuzumab
NCT00094809
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Colon Cancer, Colorectal Cancer
P2
Completed252RCT, Double-blindPlacebo, Pegfilgrastim
NCT01308840
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
Biliary Tract Cancer, Gallbladder Cancer
P2
Completed31Open-labelPanitumumab, oxaliplatin, gemcitabine
NCT00583674
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
Gastrointestinal Cancer
P2
Completed171RCT, Double-blindAMG 386 placebo, AMG 386 10mg/kg, AMG 386 3mg/kg, Cisplatin, Capecitabine, Cisplatin, Capecitabine, Cisplatin, Capecitabine
NCT00306215
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
Crohn's Disease
P2
Completed436RCT, Double-blindCCX282-B
NCT00531284
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Ovarian Cancer, Renal Cancer
P1P2
Completed184Open-labelCarfilzomib, Dexamethasone
NCT03792763
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
Multiple Myeloma
P2
Completed8RCT, Double-blindDenosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA], Placebo 1.7 ml Subcutaneous Solution
NCT00306189
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
Osteoporosis
P2
Completed212RCT, Double-blind100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo
NCT01989689
Etanercept and Vascular Function in Psoriasis
PSORIASIS
P2
Completed24RCT, Double-blindEtanercept, Placebo
NCT00418938
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Cancer, Colon Cancer
P2
Completed266RCT, Open-labelPanitumumab, Bevacizumab, Leucovorin, Irinotecan, 5-Fluorouracil
NCT00113789
Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer
Ovarian Cancer
P2
Completed21RCT, Double-blind—
NCT01285310
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
P2
Terminated237RCT, Double-blindApremilast 30 mg, Apremilast 20 mg, Placebo
NCT00425204
Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
Colorectal Cancer, Non-Small Cell Lung Cancer
P2
Completed31Open-labelPanitumumab (ABX-EGF)
NCT03703908
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
Focal Segmental Glomerulosclerosis
P2
Terminated5Open-labelCCX140-B
NCT05368103
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
Alopecia Areata
P2
Completed30Open-labelDaxdilimab
NCT00614523
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
MDS, Myelodysplastic Syndromes
P2
Completed250RCT, Double-blindPlacebo, Romiplostim
NCT00094861
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Dysphagia, Non-Small Cell Lung Cancer
P2
Completed100RCT, Double-blindPalifermin, Placebo, Paclitaxel, Carboplatin
NCT04287855
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
P2
Unknown82Open-labelIsatuximab, Carfilzomib, Pomalidomide, Dexamethasone
NCT01907308
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
Urothelial Carcinoma
P2
Withdrawn—Open-labelAMG 386, Docetaxel
NCT02802163
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Multiple Myeloma
P1P2
Withdrawn—Open-labelPanobinostat, Carfilzomib, Lenalidomide, Dexamethasone
NCT00530816
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
Multiple Myeloma
P2
Completed164Open-labelcarfilzomib
NCT01677858
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
Multiple Myeloma
P1P2
Completed116Open-labelCarfilzomib, Dexamethasone
NCT04427306
Neoadjuvant T-VEC in High Risk Early Melanoma
Melanoma
P2
SUSPENDED6Open-labelT-Vec
NCT01143038
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
Idiopathic Thrombocytopenic Purpura
P2
Completed75Open-labelRomiplostim
NCT04956809
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
HFrEF
P2
Completed3RCT, Double-blindDapagliflozin 10Mg Tab, Placebo
NCT00936650
A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)
Hyperparathyroidism, Primary
P2
Completed78RCT, Double-blindplacebo, cinacalcet
NCT00819780
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Colon Cancer, Colorectal Cancer
P2
Completed285RCT, Open-labelPanitumumab, Bevacizumab, mFOLFOX6
NCT01471782
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
P1P2
Completed93Open-labelBlinatumomab
NCT00866359
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
Behcet Syndrome
P2
Completed111RCT, Double-blindApremilast (CC-10004), Placebo
NCT04057937
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
Palmoplantaris Pustulosis
P2
Completed90RCT, Double-blindApremilast, Placebo
NCT02969837
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
Multiple Myeloma
P2
Completed46Open-labelElotuzumab, Carfilzomib, Lenalidomide, Dexamethasone
NCT02366195
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Unresected Stage IIIb to IVM1c Melanoma
P2
Completed112Open-labelTalimogene Laherparepvec
NCT01144195
A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy
Metastatic Colorectal Cancer
P2
Unknown80Open-labelPanitumumab + FOLFIRI
NCT00035607
Chemotherapy Related Anemia
Anemia, Non-Myeloid Malignancies
P2
Completed120RCT, Open-labelDarbepoetin alfa SC, Darbepoetin alfa IV
NCT00422019
A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
P2
Completed61Open-labelAMG 102 at 10 mg/kg, AMG 102 at 20 mg/kg
NCT00771030
Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis
Rheumatoid Arthritis
P1P2
Completed40RCT, Double-blindBrodalumab
NCT01775553
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Relapse Multiple Myeloma, Refractory Multiple Myeloma
P2
Completed13Open-labelCarfilzomib
NCT00752570
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Cancer, Carcinoma
P2
Completed144RCT, Double-blindAMG 386, AMG 386 Placebo, FOLFIRI
NCT00041470
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
Breast Cancer
P1P2
Terminated38Open-labelPaclitaxel, Vinorelbine, Herceptin, Filgrastim
NCT01440257
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
Diabetic Nephropathy, Type 2 Diabetes Mellitus
P2
Completed20RCT, Double-blindPlacebo, CCX140-B
NCT03584711
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
Metastatic Colorectal Cancer
P2
Completed118Open-label—
NCT00475293
Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC
Metastatic Colorectal Cancer
P2
Completed85Open-labelPanitumumab and CPT-11
NCT01233687
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
P1P2
Completed49Open-labelAMG 102 and erlotinib
NCT00035620
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Sarcoma, Neutropenia
P2
Completed44RCT, Open-labelpegfilgrastim, filgrastim
NCT03974360
Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache
Post-Traumatic Headache, Mild Traumatic Brain Injury
P2
Completed100Open-labelAMG 334
NCT00110929
Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
End Stage Renal Disease
P2
Completed850RCT, Open-labelAMG 073
NCT00111462
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
Anemia, Non-Myeloid Malignancies
P2
Completed—RCT, Open-labelDarbepoetin alfa
NCT00511459
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Locally Recurrent and Metastatic Breast Cancer
P2
Completed228RCT, Double-blindAMG 386 Placebo, AMG 386, Bevacizumab, AMG 386, AMG 386, Paclitaxel
NCT04231682
A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.
Osteoporosis
P2
Withdrawn—RCT, Double-blindDenosumab Injection, Placebos
NCT00189488
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Graft Versus Host Disease, Hematologic Malignancies
P2
Completed155RCT, Double-blindPalifermin, Placebo, Methotrexate
NCT02597062
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
Multiple Myeloma
P2
Completed76Open-labelCarfilzomib, Cyclophosphamide, Dexamethasone
NCT01150890
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
Crohn's Disease
P2
Terminated130RCT, Double-blindBrodalumab, Placebo
NCT01952574
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
Migraine
P2
Completed483RCT, Double-blindErenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
NCT00925821
Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Multiple Myeloma
P2
Completed146Open-labelRAD
NCT01199289
A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma
Asthma
P2
Completed315RCT, Double-blindAMG 827, Placebo
NCT00885885
Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases
Colorectal Cancer
P2
Completed80RCT, Open-labelPanitumumab+FOLFOX-4, Panitumumab+FOLFIRI
NCT00111423
Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
P2
Completed216RCT, Double-blindPegsunercept (PEG sTNF-RI)
NCT00446446
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Cancer, Carcinoma
P2
Completed52Open-labelPanitumumab
NCT00639717
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant
Graft Versus Host Disease
P2
Completed48Open-labeltacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
NCT03795558
A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients
End Stage Renal Disease
P2
Completed37Open-labelEtelcalcetide
NCT00002126
A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.
HIV Infections, Cytopenias
P2
Completed250—Filgrastim
NCT03839459
Denosumab for Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
P2
Completed20Open-labelDenosumab
NCT04270760
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Cardiovascular Disease
P2
Completed281RCT, Double-blindOlpasiran, Placebo
NCT02575833
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
Stable Angina
P2
Completed89RCT, Double-blindErenumab, Placebo
NCT02613416
Denosumab and MRI Breast Imaging
Breast Cancer
P2
Completed42Open-labelDenosumab
NCT00140244
Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
HAART-induced Lipodystrophy and Metabolic Syndrome
P2
Completed7RCT, Double-blindr-metHuLeptin, Placebo
NCT00773734
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
Psoriasis, Plaque-type Psoriasis
P2
Completed352RCT, Double-blindApremilast 10mg, Apremilast 20mg, Apremilast 30 mg, Placebo, Apremilast 30mg, Apremilast 20mg
NCT01305772
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN
Squamous Cell Carcinoma of the Head and Neck
P2
Terminated6Open-labelPanitumumab
NCT05669599
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Obesity, Overweight
P2
Completed592RCT, Double-blindMaridebart Cafraglutide, Placebo
NCT02215200
ATG-GCSF in New Onset Type 1 Diabetes
Diabetes Mellitus, Type 1
P2
Completed89RCT, Double-blindAnti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
NCT02429882
Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis
Axial Spondyloarthritis
P2
Withdrawn—RCT, Double-blindBrodalumab 210 mg, Placebo
NCT00682383
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Unresectable Locally Advanced NSCLC
P2
Completed26Open-labelCisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
NCT04787341
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
Colorectal Cancer
P2
Completed213RCT, Open-labelRegorafenib, Panitumumab
NCT01988103
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
Psoriasis, Psoriatic Arthritis
P2
Completed254RCT, Double-blindApremilast, Apremilast, Placebo
NCT02000427
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Philadelphia Positive B-precursor ALL
P2
Completed45Open-labelBlinatumomab
NCT03656666
The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus
Lichen Planus of Vulva, Female Genital Disease
P2
Unknown42RCT, Double-blindApremilast, Placebo
NCT00043186
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density
P2
Completed412RCT, Double-blindPlacebo, Denosumab, Alendronate
NCT03161756
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
Melanoma Stage Iv, Melanoma Stage Iii
P1P2
Unknown72Open-labelDenosumab, Nivolumab, Ipilimumab
NCT01384994
Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
Colorectal Cancer, KRAS Wildtype
P2
Unknown111RCT, Open-labelFolic Acid, 5-FU, 5-FU, Oxaliplatin, Panitumumab, Panitumumab, Folic Acid, 5-FU, 5-FU, Oxaliplatin
NCT02983097
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°)
P1P2
Terminated34Open-labelRituximab, Cisplatin, Carboplatin, Dexamethasone, Cytarabine, Lenalidomide, PegFilgrastim
NCT00117897
Treatment for Subjects With Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
P2
Completed—RCT, Open-labelpegfilgrastim, Filgrastim
NCT00808639
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Bladder Cancer, Muscle-invasive Bladder Cancer
P2
Completed39Open-labelMethotrexate, Doxorubicin, vinblastine, cisplatin, Pegfilgrastim
NCT02222155
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
ANCA-associated Vasculitis
P2
Completed42RCT, Double-blindCCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
NCT01059448
Safety and Efficacy of AMG 827 in Subjects With RA
Rheumatoid Arthritis
P2
Terminated211Open-labelAMG 827
NCT01479179
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
Breast Cancer
P1P2
Withdrawn—Open-labelAMG 479, Trastuzumab
NCT00527085
12-month Study of AMG 073 in Renal Osteodystrophy
Renal Osteodystrophy
P2
Completed45RCT, Double-blindAMG 073, Placebo
NCT00887965
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
Low Bone Mass, Low Bone Mineral Density
P2
Completed15Open-labelPrevious denosumab
NCT02096666
A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects
Stomach Neoplasms
P1P2
Completed11Open-labelAMG 337
NCT01741792
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
P2
Completed25Open-labelBlinatumomab
NCT00597909
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
Hepatic Encephalopathy
P2
Terminated1RCT, Double-blindsodium phenylacetate and sodium benzoate injection 10% / 10%, sodium phenylacetate and sodium benzoate injection 10% / 10%, placebo solution (10% dextrose)
NCT00540696
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
Anemia, Non-Myeloid Malignancies
P2
Completed300RCT, Open-labeldarbepoetin alfa
NCT01207388
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
B-cell Acute Lymphoblastic Leukemia
P2
Completed116Open-labelBlinatumomab
NCT00110942
Treatment for Patients With Osteoarthritis (OA)
Osteoarthritis
P2
Completed160RCT, Double-blindSystemic AMG 108
NCT07061080
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin
P2
Terminated1RCT, Open-labelTarlatamab, standard of care second-line chemotherapy (FOLFIRI)
NCT03422627
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease cGVHD
P1P2
Terminated32Open-labelEfavaleukin Alfa
NCT06376045
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
Asthma
P2
Terminated317RCT, Double-blindRocatinlimab, Placebo
NCT01365559
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Multiple Myeloma
P1P2
Completed39Open-labelGroup A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
NCT02014441
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Melanoma
P2
Completed61Open-labelTalimogene laherparepvec
NCT02047253
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
Metastatic Castration-resistant Prostate Cancer
P2
Completed28Open-labelCarfilzomib, Dexamethasone, Acyclovir
NCT03536754
A Study of CCX140-B in Subjects With FSGS
FSGS, Focal Segmental Glomerulosclerosis
P2
Completed46RCT, Double-blindCCX140-B, CCX140-B, CCX140-B
NCT05591222
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
Discoid Lupus Erythematosus
P2
Terminated72RCT, Double-blindPlacebo, Daxdilimab
NCT03141203
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
Peripheral T Cell Lymphoma
P1P2
Completed50Open-labelRomidepsin, Carfilzomib
NCT03600883
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
KRAS p.G12C Mutant Advanced Solid Tumors
P1P2
Completed713RCT, Open-labelsotorasib, Anti PD-1/L1, Midazolam
NCT00936988
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
Hyperparathyroidism, Primary
P2
Completed45Open-labelcinacalcet
NCT00926380
Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
Osteoporosis
P2
Completed94RCT, Open-labeldenosumab, teriparatide
NCT01502982
Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)
Diffuse Large B-Cell Lymphoma
P2
Completed160Open-labelR-CHOEP14x6+HD-AraC+HD-Mtx
NCT00005960
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Pain, Prostate Cancer
P2
Unknown——filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride
NCT00695370
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
Solid Malignancies
P2
Terminated30Open-labelPegfilgrastim (drug)
NCT01439880
Open Label Study of Long Term Evaluation Against LDL-C Trial
Hypercholesterolemia
P2
Completed1,324RCT, Open-labelEvolocumab
NCT00958386
Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)
Metastatic Colorectal Cancer
P2
Completed61Open-labelPanitumumab+irinotecan
NCT00038298
A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate
Rheumatoid Arthritis
P2
Completed53RCT, Double-blindPlacebo, AMG 719, AGM 719, AMG 719, placebo to AMG 719
NCT00894504
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
P2
Completed71Open-labelPanitumumab, Carboplatin, Gemcitabine
NCT00049985
Heart Failure and Anemia
Heart Failure, Anemia
P2
Completed300RCT, Double-blindDarbepoetin Alfa
NCT00757172
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
P2
Completed70Open-labelpanitumumab, cisplatin, docetaxel
NCT03776058
Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)
Primary Hyperparathyroidism
P2
Completed10RCT, Double-blindCinacalcet, Placebo
NCT00836277
Phase II Study of Irinotecan and Panitumumab
Esophageal Cancer
P2
Completed24Open-labelPanitumumab, Irinotecan
NCT01264328
Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer
Head and Neck Cancer
P2
Completed40Open-labelPanitumumab + paclitaxel
NCT00100477
Use of Topotecan in Patients With Refractory Acute Leukemia
Non-Hodgkin's Lymphoma, Leukemia
P2
Completed10—Topotecan, Mitozantrone, Etoposide
NCT03298412
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
High-risk Diffuse Large B-cell Lymphoma
P2
Terminated10Open-labelBlinatumomab
NCT01242917
A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
Rheumatoid Arthritis
P2
Completed159RCT, Double-blindCCX-354-C, Placebo, CCX354-C
NCT00369070
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
Advanced Non-squamous NSCLC
P2
Terminated186RCT, Open-labelBevacizumab, AMG 706, Paclitaxel, Carboplatin
NCT00436670
Phase II Study to Evaluate the Efficacy of AMG 317
Asthma
P2
Completed294RCT, Double-blindAMG 317 75 mg, AMG 317 150 mg, AMG 317 300 mg, Placebo
NCT00547157
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Cancer, Head and Neck Cancer
P2
Completed152RCT, Open-labelPanitumumab, Cisplatin
NCT00433875
Phase 2 AMG 714 in Rheumatoid Arthritis
Rheumatoid Arthritis
P2
Completed180RCT, Double-blindAMG 714
NCT00467025
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Advanced Renal Cell Carcinoma
P2
Completed152RCT, Double-blindAMG 386, Sorafenib, AMG 386 placebo IV
NCT07301424
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia
P2
Not Yet Recruiting80Open-labelTreatment with blinatumomab given subcutaneously.
NCT02807883
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
P2
Completed23Open-labelBlinatumomab
NCT00086086
Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia
Congestive Heart Failure, Anemia
P2
Completed150RCT, Double-blindDarbepoetin Alfa
NCT00586443
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
Solid Tumors
P1
Completed56Open-labelbevacizumab, everolimus, panitumumab
NCT01660750
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
Multiple Myeloma
P1
Completed29Open-labelCarfilzomib, Cyclophosphamide, Dexamethasone
NCT04293094
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
Advanced Solid Tumors
P1
Completed66Open-labelAMG 650
NCT05480865
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
Solid Tumor, Adult, Metastatic Solid Tumor
P1
Terminated28RCT, Open-labelBBP-398, sotorasib
NCT00007813
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
P1
Completed21Open-labelfilgrastim, carboplatin, cyclophosphamide, etoposide
NCT00986895
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
Hepatic Encephalopathy, Urea Cycle Disorders
P1
Completed32Open-labelHPN-100
NCT00977600
A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)
Healthy
P1
Completed24RCT, Open-labelHPN-100, Ammonul, Buphenyl
NCT03797261
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
P1
Terminated9Open-labelVenetoclax, AMG 176
NCT01549431
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
Multiple Myeloma
P1
Completed32Open-labelPanobinostat, Carfilzomib, Dexamethasone
NCT01789242
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Amyloidosis, Systemic Light Chain Amyloidosis
P1
Completed32Open-labelCarfilzomib, Dexamethasone
NCT00879385
KRAS Wild-type Metastatic Colorectal Cancer Trial
Colorectal Cancer
P1
Completed21Open-labelDacogen™ (decitabine), Vectibix® (panitumumab)
NCT03340766
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
P1
Completed31Open-labelBlinatumomab, Pembrolizumab
NCT01949545
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
Solid Tumors, Hematologic Malignancies
P1
Completed46Open-labelCarfilzomib
NCT00322400
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
Locally Recurrent and Metastatic Breast Cancer
P1
Completed46Open-labelDocetaxel, Paclitaxel, AMG 706
NCT02391259
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
P1
Completed57RCT, Double-blindAMG 557, Placebo
NCT02103283
A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
Diabetic Macular Edema
P1
Completed5Open-labelTeprotumumab
NCT02756845
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Advanced Non CNS Tumors
P1
Completed15Open-labelTalimogene Laherparepvec
NCT06563856
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
Bioavailability, Bioequivalence
P1
Completed37Open-labelTEPEZZA, EDP
NCT01980589
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Multiple Myeloma
P1
Completed22Open-labelCarfilzomib, Cyclophosphamide, Dexamethasone
NCT07422285
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Healthy Participants, Pharmacokinetics
P1
Completed405RCT, Open-labelEvolocumab Drug Substance A, Evolocumab Drug Substance B
NCT05913115
A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
Gastric or Gastroesophageal Cancer
P1
Completed6Open-labelFPA144
NCT06910709
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
Healthy Volunteers
P1
Terminated48RCT, Double-blindAMG 378, Placebo
NCT01688739
Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
Migraine
P1
Completed61RCT, Double-blindErenumab, Placebo
NCT04987333
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
Inflammatory Diseases
P1
Completed32Open-labelEfavaleukin alfa
NCT01949532
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Relapsed Multiple Myeloma, End-stage Renal Disease
P1
Completed26Open-labelCarfilzomib
NCT02961881
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
P1
Completed35Open-labelblinatumomab
NCT00040651
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Scleroderma, Systemic Sclerosis
P1
Terminated15Open-labelFludarabine, Cyclophosphamide, Thymoglobulin
NCT04887064
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
Hepatic Impairment
P1
Completed20Open-labelSotorasib
NCT06127940
K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation
Non-small Cell Lung Cancer Metastatic
P1
Unknown20Open-labelTemporary Stopping
NCT01497821
AMG 172 First in Human Study in Patients With Kidney Cancer
Renal Cell Adenocarcinoma, Clear Cell Renal Carcinoma
P1
Completed37Open-labelAMG 172
NCT01386866
Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
P1
Completed4Open-labelAMG 706
NCT01634178
Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults
Healthy Volunteer
P1
Completed46RCT, Open-labelApremilast
NCT07226778
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
Overweight, Obesity
P1
Completed348RCT, Open-labelMaridebart Cafraglutide
NCT06131398
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Advanced Solid Tumors
P1
Completed77Open-labelAMG 355, Pembrolizumab
NCT01723514
Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients
Migraine
P1
Completed48RCT, Double-blindErenumab, Placebo
NCT00813384
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
Cancer, Oncology
P1
Completed54Open-labelAMG 208
NCT01999335
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
P1
Terminated33Open-labelOprozomib, Pomalidomide, Dexamethasone
NCT03156023
Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis
Rheumatoid Arthritis
P1
Completed34RCT, Double-blindRozibafusp Alfa, Placebo
NCT01294397
Effects of Denosumab on the Pharmacokinetics of Etanercept
Postmenopausal, Osteopenia
P1
Terminated19Open-labelEtanercept, Denosumab
NCT00635596
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Solid Tumors
P1
Completed65Open-labelMT110
NCT00513383
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
P1
Completed34Open-labelPanitumumab, Carboplatin, Paclitaxel, 5-Fluorouracil, Docetaxel, Cisplatin
NCT02675452
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
P1
Terminated141Open-labelAMG 176, Azacitidine, Itraconazole
NCT06438263
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
Atopic Dermatitis
P1
Completed231RCT, Open-labelRocatinlimab, Rocatinlimab
NCT04362748
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
Advanced Solid Tumors
P1
Completed34Open-labelAMG 256
NCT02293109
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma
P1
Completed10Open-labelcarfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone, rituximab
NCT05045638
Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
Healthy Participants
P1
Completed13Open-labelRosuvastatin, Sotorasib
NCT00361634
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis
Rheumatoid Arthritis
P1
Completed14Open-labelEtanercept
NCT03430687
Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
P1
Withdrawn—Open-labelTalimogene Laherparepvec
NCT02618967
Single Ascending Dose Study of AMG 570 in Healthy Subjects
Systemic Lupus Erythematosus
P1
Completed56RCT, Double-blindAMG 570, AMG 570 Matching Placebo
NCT03757130
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
Obesity
P1
Completed50RCT, Double-blindAMG 598, Placebo, Liraglutide
NCT02054572
Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
P1
Completed6Open-label[¹⁴C]Etelcalcetide
NCT02170337
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
P1
Completed41RCT, Double-blindAMG 282, Placebo
NCT02099461
Effect of Denosumab on Cellular Biomarkers in the Human Breast
Healthy Volunteer, Female, Breast
P1
Completed82RCT, Open-labelDenosumab
NCT00448786
Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors
Solid Tumors
P1
Completed49RCT, Open-labelAMG 706, AMG 706, AMG 706
NCT01510951
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis
Psoriasis
P1
Completed9RCT, Double-blindAMG 811 or Placebo
NCT05056246
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
Healthy Participants
P1
Completed34RCT, Open-labelAMG 133
NCT00002255
An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)
HIV Infections
P1
Completed—Open-labelFilgrastim, Epoetin alfa, Zidovudine
NCT04478708
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
Obesity
P1
Completed110RCT, Double-blindmaridebart cafraglutide, Placebo
NCT00102830
Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors
Tumors
P1
Completed——AMG 386
NCT05988008
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
P1
Completed80RCT, Single-blindCCX168, Placebo
NCT07717814
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity
Overweight and Obesity
P1
Completed154RCT, Open-labelAMG 133 (frozen liquid), AMG 133 (liquid)
NCT07545226
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
Healthy Participants
P1
Completed405RCT, Open-labelEvolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference)
NCT00756860
A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
Healthy Volunteers
P1
Completed66RCT, Open-labelAMG 223, Renagel® (sevelamer hydrochloride)
NCT02504476
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
Schizophrenia or Schizoaffective Disorder
P1
Completed52RCT, Double-blindAMG 581, Placebo, Midazolam
NCT02275156
Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab
Hyperlipidemia, Mixed Dyslipidemia
P1
Completed18Open-labelEvolocumab
NCT04478695
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Relapsed or Refractory Acute Myeloid Leukemia
P1
Terminated1Open-labelAMG 330, Pembrolizumab
NCT00150462
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma
P1
Completed48Open-labelCarfilzomib, Dexamethasone
NCT01212380
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer
P1
Completed21Open-labelcarfilzomib
NCT03465540
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Multiple Myeloma, Acute Myeloid Leukemia
P1
Terminated24Open-labelAMG 397, Dexamethasone, Azacitidine
NCT01300026
AMG 319 Lymphoid Malignancy FIH
Cancer, Chronic Lymphocytic Leukemia
P1
Completed28Open-labelAMG 319
NCT01405963
Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma
Asthma
P1
Completed31RCT, Double-blindPlacebo, Tezepelumab
NCT01926665
Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)
Lymphoma
P1
Completed2Open-labelCarfilzomib, Dexamethasone
NCT01122199
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
Neoplasm Metastases
P1
Completed27Open-labelRAD001 + AMG479
NCT00112385
A Pilot Study of Etanercept in Dermatomyositis
Dermatomyositis
P1
Completed16RCT, Double-blindEtanercept, Placebo
NCT00101894
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Rectal Cancer, Colon Cancer
P1
Completed119Open-labelFOLFOX-4, AMG 706, Panitumumab (Part 1a only), FOLFIRI
NCT04673630
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
Asthma
P1
Completed18Open-labelTezepelumab
NCT04545554
Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
Osteogenesis Imperfecta
P1
Completed25Open-labelRomosozumab
NCT02520427
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Relapsed/Refractory AML, Minimal Residual Disease Positive AML
P1
Terminated95Open-labelAMG 330
NCT00840333
"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"
Cystic Fibrosis
P1
Completed27RCT, Open-labelMP-376 (Levofloxacin solution for Inhalation)
NCT02833857
A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis
Chronic Kidney Disease, Secondary Hyperparathyroidism
P1
Completed11Open-labelEtelcalcetide
NCT00997022
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
Hepatocellular Cancer
P1
Completed14Open-labelSorafenib
NCT06004947
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
P1
Completed32Open-labelCCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
NCT04524455
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
Acute Lymphoblastic Leukemia
P1
Completed17Open-labelBlinatumomab, AMG 404, Dexamethasone Premedication
NCT04478994
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Diffuse Cutaneous Systemic Sclerosis
P1
Terminated3RCT, Double-blindTEPEZZA
NCT00757042
Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis
Atopic Dermatitis, Healthy Volunteers
P1
Completed78RCT, Double-blindTezepelumab, Placebo
NCT01588509
Transition From Alendronate to Romosozumab (AMG 785)
Osteoporosis
P1
Completed60RCT, Open-labelRomosozumab
NCT01890109
Study of Erenumab (AMG 334) in Women With Hot Flashes
Vasomotor Symptoms; Hot Flashes
P1
Completed103RCT, Double-blindErenumab, Placebo
NCT03318809
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function
Heart Failure
P1
Completed12Open-labelAMG 986
NCT00091806
Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
Tumors, Oncology
P1
Completed86Open-labelpanitumumab (ABX-EGF), Panitumumab
NCT07429045
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
Overweight and Obesity
P1
Completed44Open-labelAMG 133
NCT02318407
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain
Osteoarthritis
P1
Completed24RCT, Double-blindAMG 403, Placebo
NCT02741310
Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan
Healthy Subjects
P1
Completed34RCT, Double-blindPlacebo, Sumatriptan, Erenumab
NCT01953341
Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines
Migraine
P1
Completed74RCT, Double-blindAMG 333, Placebo
NCT00972179
Safety Study of Tezepelumab (AMG 157) in Healthy Adults
Healthy Volunteers
P1
Completed49RCT, Double-blindPlacebo, Tezepelumab
NCT05598281
Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants
Healthy Participants
P1
Completed14Open-labelAMG 510, Digoxin
NCT01290042
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
Ulcerative Colitis, Crohn's Disease
P1
Completed43RCT, Double-blindAMG 181
NCT00902356
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
Osteopenia
P1
Completed69RCT, Double-blindAMG 167, Placebo
NCT01493518
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
Psoriasis
P1
Terminated6RCT, Double-blindAMG 557 or PLACEBO
NCT05578859
A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects
Healthy Subjects
P1
Completed8Open-labelAMG 510
NCT00186602
Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?
Breast Cancer
Completed———
NCT01139918
Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis
Psoriatic Arthritis, Psoriasis
Completed105——
NCT05360225
Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit
Non Small Cell Lung Cancer
Completed5,000——
NCT02520362
Denosumab Safety Assessment in Multiple Observational Databases
Osteoporosis
Completed517,991—denosumab, bisphosphonate
NCT05245851
Clinical Deployment and Validation of Rho
Low Bone Density
N/A
Completed1,146Open-label—
NCT02922179
Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics
Diabetes
Completed103,951—Long- and intermediate- acting insulins
NCT02921191
Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated
Breast Cancer, Lung Cancer
Completed57,725—filgrastim, TBO-filgrastim or pegfilgrastim
NCT02922192
Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis
Rheumatoid Arthritis, Inflammatory Bowel Disease
Completed90,360—TNF-α antagonists, non-TNFs, DMARD non-biologics
NCT05826756
Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting
Lung Cancer Patients, Caregivers
Unknown1,300——
NCT06585189
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
Metastatic Non Small Cell Lung Cancer
Completed304—Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
NCT05347745
Therascreen® KRAS RGQ PCR Kit
Colo-rectal Cancer
N/A
Completed219Open-label—
NCT05347797
Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit
Non-small Cell Lung Cancer
N/A
Completed495Open-label—
NCT06607393
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
Metastatic Nonsmall Cell Lung Cancer
Completed851—Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
NCT06607601
CARE Initiative: Real-world Emulation of the PALOMA-2 Trial
Metastatic Breast Cancer
Completed724—Palbociclib, Letrozole
NCT05348187
Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
Non-Small Cell Lung Cancer, Colorectal Cancer
N/A
Completed309Open-label—
NCT00472290
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
Hematology, MDS
N/A
Completed72Open-labelRomiplostim (formerly AMG 531)
NCT01948427
Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)
Urea Cycle Disorder
Terminated203——
NCT02808403
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
Hypercholesterolemia, Familial Hypercholesterolemia
Completed6,000——
NCT05891119
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Early P1
Completed21Open-labelMetoprolol, Midazolam, Warfarin, Omeprazole, Rocatinlimab
NCT03970902
Quality of Life in Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
Completed239——
NCT01122095
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Psoriasis, Obesity
Unknown100——
NCT03691311
Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer
Breast Neoplasm Female, Stage I Breast Cancer
Early P1
Unknown60RCT, Open-labelDenosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
NCT00413400
Study of TNF-Antagonism in the Metabolic Syndrome (II)
Metabolic Syndrome
N/A
Completed40RCT, Double-blindEtanercept, Placebo
NCT00615901
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Breast Cancer
N/A
Completed38Open-labelcyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
NCT02783651
An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
Relapsed/Refractory Acute Lymphoblastic Leukemia
Completed212——
NCT00002037
Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study
Mycobacterium Avium-Intracellulare Infection, HIV Infections
N/A
Completed15Open-labelTrifluridine
NCT03096990
A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium
Arthritis, Psoriatic
Completed106—apremilast
NCT04645420
Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients
Psoriatic Arthritis
N/A
Completed19Open-label—
NCT00283621
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
Sarcoma
N/A
Completed51Open-labelAranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide
NCT04220164
Observation of Blood Lipid Outcomes in Lipid Clinic
Dyslipidemias
Unknown500——
NCT03139630
COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients
HIV Seropositivity, Dyslipidemias
Completed193——
NCT01842776
Care Transitions in Renal Disease Patients
Renal Disease
Unknown3,300——
NCT03398954
a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia
Familial Hypercholesterolemia
Unknown1,128——
NCT02851732
Brazilian inteRvention to Increase eviDence usaGe in practicE - Cardiovascular Prevention
Cardiovascular Diseases
N/A
Completed1,623RCT, Single-blind—
NCT01666106
Osteonecrosis of the Jaw (ONJ) Case Registry
Osteonecrosis of the Jaw
Completed327——
NCT01191385
GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
Carcinoma, Hepatocellular
Withdrawn——Any treatment for unresectable HCC as chosen by the physician
NCT04478227
TPO-Mimetic Use in Children for Hematopoietic Failure
Bone Marrow Failure Disorders, Aplastic Anemia
Early P1
Completed15Open-labelRomiplostim
NCT00861224
Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology
Idiopathic Thrombocytopenic Purpura
Completed10——
NCT05256446
AMG 701 Expanded Access Program
NO_LONGER_AVAILABLE——AMG 701
NCT05171270
AsseSSing Impact in pSoriatic Treatment
Psoriatic Arthritis
Completed503——
NCT03224819
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Early P1
Terminated46Open-labelEmerfetamab
NCT01541072
Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation
Non Hodgkin Lymphoma
N/A
Terminated34RCT, Open-labelPegfilgrastim, Filgrastim
NCT00355407
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
Hematologic Malignancies
N/A
Completed31Open-labelDarbepoetin alfa
NCT00189501
A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)
Nephrology
Completed1,000—Sensipar®
NCT00930592
Peds Metabolic Syndrome in Psoriasis
Psoriasis, Metabolic Syndrome
Completed42——
NCT00002281
A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex
HIV Infections, Cytopenias
N/A
Completed24Open-labelFilgrastim, Epoetin alfa, Zidovudine
NCT05669040
mHealth to Improve the Experience, Adherence to Drug Treatment and Positive Mental Health
Fracture of Femur
N/A
Unknown278Single-blind—
NCT00477191
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Psoriasis, Metabolic Syndrome
N/A
Terminated18Open-labelEtanercept
NCT02287610
A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Completed75—RAYOS (delayed-release prednisone)
NCT02435147
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Osteoporosis, Bone Fracture
Completed86—denosumab
NCT03097003
A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium
Psoriasis
Completed124—Apremilast
NCT00512499
Strategies to Treat Osteoporosis Following a Fragility Fracture
Osteoporosis, Fractures
N/A
Completed1,410RCT, Single-blind—
NCT06576050
WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise
Heart Failure, Obesity
Completed21——
NCT01791361
Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe
Metastatic Colorectal Cancer
Completed439——
NCT07355894
Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
N/A
Not Yet Recruiting120,000RCT, Open-label—
NCT02626793
A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions
Psoriasis
Completed391——
NCT05273047
RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC
Nsclc, KRAS P.G12C
Unknown458——
NCT00928408
PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
Hyperparathyroidism, Primary
Completed305—Cinacalcet
NCT00617370
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
Breast Cancer, Adenocarcinoma of the Breast
N/A
Completed38Open-labelepirubicin, cyclophosphamide, Paclitaxel,
NCT02303522
Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Completed207——
NCT02173171
Registry Study for Talimogene Laherparepvec
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
Completed185——
NCT05542719
Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular
Secondary Prevention, Cardiovascular Disease With Mention of Arteriosclerosis
Unknown13,166——
NCT00802815
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Inclusion Body Myositis
Early P1
Completed20RCT, Double-blindEtanercept
NCT06761703
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
Obesity
Completed200——
NCT07883564
Improving Implementation of Guideline-Recommended LDL-C Management in High-Risk Cardiovascular Patients
ASCVD
Not Yet Recruiting2,500——
NCT02185911
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
Anaemia, Chronic Kidney Disease (CKD)
Completed308——
NCT04654364
Lung Cancer Registry
Lung Cancer, NSCLC Stage IV
Completed290——
NCT00115128
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors
Normal PBPC Donors
Completed309—filgrastim
NCT03091127
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
Multiple Myeloma
Completed705——
NCT03757013
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Psoriasis
Completed453—Apremilast
NCT00094822
Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer, Non-Small Cell Lung Cancer
Completed90——
NCT06140095
Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism
Acute Metabolic Effects of Evolocumab and Atorvastatin
Early P1
Unknown8Open-labelEvolocumab
NCT04197453
The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
ASCVD
Terminated752——
NCT05495620
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Unknown300—Carfilzomib, Lenalidomide, Dexamethasone
NCT07143513
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
Non-Small Cell Lung Cancer
Completed102—Sotorasib
NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin
N/A
Completed500Open-labelRituximab, Epratuzumab
NCT01156090
A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
Infusion Reaction
Completed141——
NCT02740218
A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
Psoriasis
Completed610——